Journal article
Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice
CPW Soon, PJ Crouch, BJ Turner, CA McLean, KM Laughton, JD Atkin, CL Masters, AR White, QX Li
Neuromuscular Disorders | Published : 2010
Abstract
Amyotrophic lateral sclerosis (ALS) is an adult-onset fatal neurodegenerative disorder characterized by progressive deterioration of motor neurons in the spinal cord, brainstem, and cerebral cortex. Matrix metalloproteinase-9 (MMP-9) is proposed to be a biomarker for ALS due to a potential pathological role in the disease. However, despite numerous studies, it is still unclear whether there is a direct correlation between MMP-9 expression in serum and progression of disease. Therefore, we used a TgSOD1G93A mouse with a low transgene copy number. This model shows slow disease progression analogous to human ALS and provides a useful model to study biomarker expression at different stages of di..
View full abstractRelated Projects (1)
Grants
Awarded by Motor Neurone Disease Research Institute of Australia
Funding Acknowledgements
We thank Dr. Su San Mok for comments. This work was supported in part by NHMRC program Grant #400202, CJ Martin Fellowship #359269 (BJT), the Bethlehem Griffiths Research Foundation, and the Motor Neurone Disease Research Institute of Australia.